| Q34220578 | Adolescent and young adult HPV vaccination in Australia: achievements and challenges. |
| Q51557810 | Aggregation and competitive exclusion: explaining the coexistence of human Papillomavirus types and the effectiveness of limited vaccine conferred cross-immunity. |
| Q51434146 | Assessing HPV vaccine coverage in Australia by geography and socioeconomic status: are we protecting those most at risk? |
| Q41637628 | Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program |
| Q28245583 | Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study |
| Q35922347 | Associations Between Exposure to and Expression of Negative Opinions About Human Papillomavirus Vaccines on Social Media: An Observational Study |
| Q36114121 | Attitudes, Knowledge and Factors Associated with Human Papillomavirus (HPV) Vaccine Uptake in Adolescent Girls and Young Women in Victoria, Australia |
| Q38065295 | Australia's contribution to global immunisation |
| Q50725939 | Barriers to better three-dose coverage with HPV vaccination in school-based programs. |
| Q41541977 | Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial. |
| Q39224081 | Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand |
| Q34626578 | Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program |
| Q38244662 | Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries |
| Q44222617 | Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study |
| Q37616577 | Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. |
| Q42286605 | Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States. |
| Q56767722 | Ethical Challenges in School-Based Immunization Programs for Adolescents: A Qualitative Study |
| Q87088117 | HPV vaccination in women treated for CIN2/3: it's still all about prevention |
| Q44900620 | Herd immunity effect of the HPV vaccination program in Australia under different assumptions regarding natural immunity against re-infection. |
| Q55385410 | Human Papillomavirus and Oropharyngeal Cancer Among Indigenous Australians: Protocol for a Prevalence Study of Oral-Related Human Papillomavirus and Cost-Effectiveness of Prevention. |
| Q34704575 | Human papilloma virus vaccination: impact and recommendations across the world |
| Q51179023 | Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: independent estimates from a nationally representative mobile phone survey. |
| Q34987731 | Human papillomavirus 16/18 seroprevalence in unvaccinated women over 30 years with normal cytology and with high grade cervical abnormalities in Australia: results from an observational study |
| Q34731097 | Human papillomavirus type 6 and 11 genetic variants found in 71 oral and anogenital epithelial samples from Australia |
| Q38218612 | Human papillomavirus vaccination: where are we now? |
| Q35044376 | Immunoprevention of human papillomavirus-associated malignancies |
| Q30682187 | Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study |
| Q38373388 | Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination |
| Q40816025 | Measuring HPV vaccination coverage in Australia: comparing two alternative population-based denominators |
| Q34777452 | Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study) |
| Q37198208 | Modeling preventative strategies against human papillomavirus-related disease in developed countries |
| Q45950453 | Parental and societal support for adolescent immunization through school based immunization programs. |
| Q36069114 | Parents' Recall and Reflections on Experiences Related to HPV Vaccination for Their Children |
| Q35790310 | Parents' views on human papillomavirus vaccination for sexually transmissible infection prevention: a qualitative study |
| Q38182714 | Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer |
| Q28262413 | Practice- and Community-Based Interventions to Increase Human Papillomavirus Vaccine Coverage: A Systematic Review |
| Q90337276 | Prevalence of human papillomavirus in teenage heterosexual males following the implementation of female and male school-based vaccination in Australia: 2014-2017 |
| Q49644195 | Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia |
| Q91766049 | Reaching 80% human papillomavirus vaccination prevalence by 2026: How many adolescents need to be vaccinated and what are their characteristics? |
| Q37473145 | Ten years of anti-HPV vaccinations: what do we know? |
| Q30764433 | Testing previous model predictions against new data on human papillomavirus vaccination program outcomes |
| Q41563548 | The effect of making a 'third dose assumption' on HPV coverage estimates |
| Q33769284 | The potential impact of HPV-16 reactivation on prevalence in older Australians. |
| Q92178995 | The situation of vaccines for the prevention of infections in adults: An opinion paper on the situation in Spain |
| Q34812959 | Towards the eradication of HPV infection through universal specific vaccination |